Long-term outcomes and dynamics of mutants associated with lamivudine-adefovir rescue therapy in patients with lamivudine-resistant chronic hepatitis B.
Abstract: The population of rtM204 mutants persisted or increased in 8 of 12 patients, and rtA181T mutants newly emerged as a minor population in four patients until 96 weeks.
Result: However, none of these four patients who developed the rtA181T mutation showed virological breakthrough during 96 weeks of LAM-ADV combination therapy.
Result: LAM-resistant (rtL180M and rtM204I/V) and ADV-resistant (rtA181V/T and rtN236T) mutation profiles were followed through RFMP assay at weeks 48 and 96 of the combination therapy.
Analysis of HBV genotype, drug resistant mutations, and pre-core/basal core promoter mutations in Korean patients with acute hepatitis B.
Abstract: No patient showed mutations that conferred resistance against lamivudine (L180M, M204V/I), adefovir (A181T, N236S), or entecavir (I169M, A184T/V, S202I/G, M250V/I/L).
Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.
Abstract: CONCLUSION: The HBV rtA181T mutation is closely associated with adefovir and lamivudine exposure.rtA181T may led to sW172*, culminating in suppression of HBsAg secretion.However, co-existence of the mutant with wild-type sequences was common among our patient population, suggesting that the mutation had little impact on serum HBsAg and HBV DNA levels across the clinical study population.
Abstract: METHODS: Serum samples from 3, 013 patients who visited The 302 Hospital (Beijing, China) were investigated.HBV DNA was extracted and HBV mutations and genotypes were determined by direct sequencing.Recombinant plasmids harboring the rtA181T/
Microarray-based genotyping and detection of drug-resistant HBV mutations from 620 Chinese patients with chronic HBV infection.
PMID: 25982306
2015
The Brazilian journal of infectious diseases
Abstract: Of these, nine and eight patients carried lamivudine (LAM)-/telbivudine (LdT)-resistance mutations (rtL180M, rtM204I/V) and adefovir (ADV)-resistance mutations (rtA181T/V, rtN236T), respectively.
Virological Characteristics of Acute Hepatitis B in Eastern India: Critical Differences with Chronic Infection.
Result: There were no drug resistant mutations (lamivudine-resistant pattern: rtM204V/I, rtL180M, rtV173L, adefovir-resistant pattern: rtA181V/T, tenofovir-resistant pattern: rtA194T and entecavir-resistant pattern: rtL180M, rtS202G, rtM204V) detectable in acute patients belonging to our study population.
Epidemiology study of HBV genotypes and antiviral drug resistance in multi-ethnic regions from Western China.
Discussion: HBV mutation rtA181T/V and rtN236T could lead to drug resistance of ADV, and the influence of HBV genotypes on the resistance to ADV has not been clarified.
Discussion: It was noteworthy that ADV-associated mutation rtA181T was considered as a cross-resistant mutation, which could induce resistance to LMV and LdT in patients never exposed to these antiviral drugs.
Discussion: Patients infected with genotype C had a higher rate of mutant
Discussion: analyzed HBV sequences from 1236 CHB patients and found significantly higher frequency of rtA181T in HBV genotypes C isolates compared to genotypes D and A isolates (63.8% vs.
Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy.
Method: In cases with rtA181T mutants, the decreased packaging efficiency of the deficient S protein was coupled with the enhanced activity of the mutated RT enzyme under NA treatment.
Method: The observed change of rtA181T and rtM204I mutant frequencies in the PVR and VB groups enabled us to assign parameters for the aforementioned dynamic model and further explore the mechanism of HBV dynamics during antiviral therapy (details are presented in Supplementary Text S4).
Method: We separately specified the total amounts of rtA181T, rtM204I mutants, and drug-sensitiv
Efficacy of tenofovir disoproxil fumarate therapy in nucleoside-analogue naive Iranian patients treated for chronic hepatitis B.
Result: No patient harbored previously described amino acid substitutions, including substitutions that could be associated with reduced TDF susceptibility (rtA181V/T, rtN236T or rtA194T).
Detection and analysis of resistance mutations of hepatitis B virus.
PMID: 26309637
2015
International journal of clinical and experimental medicine
Abstract: L180M, M204I and M204V were associated with the resistance to lamivudine and telbivudine; L180M, M204I, M204V and V173L were associated with the resistance to entecavir; A181T, N236T and N/H238T were related to the resistance to adefovir.
Substitution at rt269 in Hepatitis B Virus Polymerase Is a Compensatory Mutation Associated with Multi-Drug Resistance.
HBV mutation literature information.
PMID: 
2015
Gut and liver
Browser Board
Co-occurred Entities
Filtrator
ViMRT